Anaplasia (unfavorable histology) is associated with therapy resistance and poor prognosis of Wilms tumor, but the molecular basis for this phenotype is unclear. Here, we used a cDNA array with 9240 clones relevant to cancer biology and/or kidney development to examine the expression profiles of 54 Wilms tumors, five normal kidneys and fetal kidney. By linking genes differentially expressed between fetal kidney and Wilms tumors to kidney morphogenesis, we found that genes expressed at a higher level in Wilms tumors tend to be expressed more in uninduced metanephrogenic mesenchyme or blastema than in their differentiated structures. Conversely, genes expressed at a lower level in Wilms tumors tend to be expressed less in uninduced metanephrogenic mesenchyme or blastema. We also identified 97 clones representing 76 Unigenes or unclustered ESTs that clearly separate anaplastic Wilms tumors from tumors with favorable histology. Genes in this set provide insight into the nature of the abnormal nuclear morphology of anaplastic tumors and may facilitate identification of molecular targets to improve their responsiveness to treatment.
Introduction
Wilms tumors are histologically heterogeneous and contain structures that mimic those present during normal nephrogenesis. Thus, Wilms tumor is thought to arise from nephrogenic mesenchymal cells that have failed to complete the mesenchymal-epithelial transition (MET) and is studied as a paradigm for arrested differentiation leading to human cancer (Mierau et al., 1987; Hastie, 1994) . A recent study comparing global gene expression between six Wilms tumors and six fetal kidneys using Affymetrix U95A Genechips demonstrated that Wilms tumors systematically overexpress genes corresponding to the earliest stage of metanephric development and underexpress genes corresponding to later stages (Li et al., 2002) . This study supports the notion that cells in Wilms tumors are arrested in their differentiation at an early stage of metanephric development, but it does not provide insights into how genes involved in morphogenesis during kidney development, especially the MET, might contribute to tumorigenesis.
Anaplastic Wilms tumor is defined histologically by the presence of cells with three characteristic nuclear features: enlarged nuclei, multipolar mitotic figures and hyperchromasia (Zuppan et al., 1988) . Although it is relatively rare (3.2-7.3% of all Wilms tumors), this subset of tumors is clinically important since anaplastic tumors are typically resistant to therapy and have poor prognosis (Beckwith and Palmer, 1978; Bonadio et al., 1985) . The molecular basis for the anaplastic phenotype is unknown; however, unlike Wilms tumors with favorable histology (FH), most anaplastic tumors contain somatic p53 mutations (Bardeesy et al., 1994 (Bardeesy et al., , 1995 . In the present study, we utilized a custom cDNA array containing 4900 Unigenes or unclustered ESTs (9240 clones) relevant to cancer biology and/or kidney development to examine gene expression profiles of 54 Wilms tumors, and established a gene expression connection between Wilms tumor and kidney morphogenesis, as well as identified a gene expression signature that differentiates anaplastic Wilms tumors from those with FH.
Results

Hierarchical clustering of Wilms tumors based on gene expression profiles
Gene expression data were obtained for 4900 cancer-or kidney development-related genes (9240 cDNA clones) in five normal kidneys, two Wilms tumor cell lines and 54 Wilms tumors. Unsupervised hierarchical clustering using the 2000 clones that showed the greatest variation in expression among the 61 samples clearly separated the normal kidneys from Wilms tumors and Wilms tumor cell lines, indicating that Wilms tumors have distinct gene expression profiles from normal kidneys ( Figure 1 ). This is expected due to oncogenic changes in the tumors and due to the fact that normal kidneys are fully differentiated, consisting mostly of epithelial cells without the blastemal and stromal cell components usually found in Wilms tumors. Therefore, this serves as indicator for the high quality of the array data. It also suggests that there is little, if any, crosscontamination of normal kidney tissues with tumor tissues. Notably, the replicate samples for two Wilms tumors clustered together (Figure 1 ), also providing high confidence in the reliability and reproducibility of the array data.
Gene expression connection between Wilms tumorigenesis and kidney morphogenesis
To explore links between Wilms tumorigenesis and normal kidney development, we analysed gene expression differences between Wilms tumor samples and human normal fetal kidney. For a closer comparison, only early-stage tumors (I or II, n ¼ 31) were included in this analysis. These tumors were each compared to the same pooled human normal fetal kidney sample (13-24 weeks of gestation). Gene expression in this fetal kidney sample is expected to represent developmentally expressed genes, since human nephrogenesis occurs between the 8th and 32nd week of gestation (Lechner and Dressler, 1997; Bard, 2002) . We identified 931 clones that were upregulated (see Materials and methods for selection criteria) in Wilms tumors as compared to normal fetal kidney and 1130 clones that were downregulated. Notably, we found that the results obtained from this pooled fetal kidney sample were compatible to those obtained in a recent study using multiple fetal kidney samples (Li et al., 2002) . Among the 96 genes that were identified as differentially expressed between Wilms tumors and fetal kidneys by both us and Li et al.
(they compared six Wilms tumors and six normal fetal kidneys using Affymetrix Genechips) (Li et al., 2002) , 92 genes have the same expression pattern (either up-or downregulated in Wilms tumors). This supports the validity of using a pooled fetal kidney sample. Through comparison with a rat kidney development data set (Stuart et al., 2001) , we found that 36 of 50 genes (72%) upregulated in Wilms tumors are more abundantly expressed in the early stages of kidney development. In contrast, 67 of 82 genes (82%) downregulated in Wilms tumors are preferentially expressed in the later stages of kidney development. This result is similar to that observed by Li et al. (2002) .
We next linked the differentially expressed genes in Wilms tumor to normal nephrogenesis by exploring a kidney development database (golgi.ana.ed.ac.uk/kidhome.html) and literature (Table 1, see Supplementary  Table 1 for a complete list and developmental expression patterns). Among these genes, we focused on those falling into one of the following categories. Genes in Category 1 have been implicated in kidney development either by functional studies or by showing differential expression during nephrogenesis, especially in different morphogenic structures as shown in Figure 2 . Genes in Category 2 are involved in development in general or of organs other than kidney according to PubMed searches or SOURCE searches (http://genome-www5.stanford. edu/cgi-bin/source/sourceSearch), and have been implicated in Wilms tumor or other cancers. Category 3 includes genes that have not been definitively stated to be involved in development in the GeneReports compiled by the SOURCE program, but whose mRNA levels changed during rat nephrogenesis as measured by global gene expression profiling (Stuart et al., 2001) and have been implicated in Wilms tumor. For those genes in Category 1 that are implicated in kidney development, it appears that the genes we found to be overexpressed in Wilms tumors tend to be expressed higher in the metanephric mesenchyme (MM) than in the ureteric bud (UB) or UB branching derivatives, and their expression levels decrease as the MM differentiates. This group includes MEOX1, SET, NCAM, p75/NGFR and IGF2 identified from the kidney development database (http://golgi.ana.ed.ac. uk/kidhome.html) and N-myc (Mugrauer et al., 1988; Stanton and Parada, 1992; Bates et al., 2000) . On the other hand, genes underexpressed in Wilms tumors tend to be expressed higher in differentiated structures (such as glomerulus or nephron) than in MM or its early differentiating derivatives (such as blastema or condensates). These genes include Lim-1, PDGFA, BMP7, VEGF, CDH1, CDH6, COL4A1, COL4A2, COL5A1, COL5A2 and ITGA2 (all identified from the kidney development database) and AGT (Niimura et al., 1997) , SDC1 (Cook et al., 1996) , TYRO10/DDR2 (Stuart et al., 2003) , FGFR3 (Cancilla et al., 1999) , frizzled homolog 1 (FZD1) (Lechner and Dressler, 1997), c-myc (Harding et al., 1992) , TGFA (Diaz-Ruiz et al., 1993) , TGFBR2 (Wang et al., 1995) and THBS1 (Kang et al., 2001) (Supplementary Table 1) (Figure 2) .
Genes in Categories 2 and 3 may represent new nephrogenic genes that are also involved in Wilms tumorigenesis. Accordingly, we performed immunohistochemical (IHC) staining for a representative of these genes, stathmin 1, to further assess its protein expression patterns in fetal kidneys, mature kidneys and Wilms tumors. IHC staining on a Wilms tumor tissue array showed that stathmin 1 protein was expressed at much higher levels in Wilms tumors than in normal adjacent kidneys. Positive immunostaining was observed in 16 of 17 tumor samples, while in none of 15 normal adjacent kidney samples (Figure 3a and data not shown). Stathmin 1 protein expression in a 25-week human fetal kidney sample was restricted to areas undergoing active differentiation and proliferation with little expression in differentiated structures, such as glomeruli (Figure 3b) .
A gene expression signature for anaplastic Wilms tumors
Among the 54 Wilms tumors analysed by cDNA arrays, 40 had FH and eight were anaplastic. The remaining six tumors consisted of one tumor (T40) analysed on a 
WT: Wilms tumor; FK: fetal kidney. *One sample t-test P-value (two-sided).
a Category 1, 2 and 3 as discussed in text.
different batch of cDNA arrays and five tumors representing disease progression in three patients. These included primary tumor T4 and its metastasis T16, primary tumor T54 and its metastasis T53, and metastatic tumor T47 (Supplementary Table 2 for clinical information).
To study the gene expression patterns associated with anaplasia, the 48 FH and anaplastic tumors were grouped together and three methods were applied to identify differentially expressed genes, including Welch's t-test with multiple testing correction (Benjamini and Hochberg False Discovery Rate), SAM (significance analysis of microarray) and PAM (prediction analysis of microarray). A total of 47 clones had an adjusted Pvalue of o0.05 in the Welch's t-test with multiple testing correction. Unsupervised hierarchical clustering based on these 47 clones grouped anaplastic tumors as a cluster, but this cluster was not separated from FH tumors ( Figure 4a ). The classification accuracy in crossvalidation for these 47 clones was 87.5%. SAM selected a set of 101 clones (false significance rate of 9.5%) that separated anaplastic tumors from FH tumors except for one FH tumor being clustered with anaplastic tumors (Figure 4b ) and its classification accuracy was 93.8%. PAM identified a set of 97 clones that clearly separated all anaplastic tumors from FH tumors and correctly classified 46/48 tumors (95.8%) in crossvalidation ( Figure 4c ). A total of 83 clones were identified in common by both SAM (out of 101 clones) and PAM (out of 97 clones).
It has been suggested that anaplastic tumors progress from FH tumors by clonal expansion of tumor cells acquiring p53 deficiency along with other unknown changes (Bardeesy et al., 1995) . Accordingly, we searched our data for support of this hypothesis. Using the 48 tumor samples as a training set, the 97 anaplasiaassociated clones identified by PAM were used to predict the histology of the six tumor samples excluded from the original analysis. Primary tumors T4 (FH) and T40 (FH), primary tumor T54 (FH) and its metastasis tumor T53 (anaplastic) were correctly predicted. Notably, metastatic tumor T16, which was derived from T4 (primary, FH), was predicted to be anaplastic. It is unknown to us whether the T16 tumor had anaplasia or FH when these data analyses were performed. On subsequent histological re-evaluation, this case was determined to be anaplastic. The metastatic tumor T47 derived from T46 (primary, anaplastic, included in the 48 tumors) was also predicted to be anaplastic. Interestingly, the pathology report for tumor T47 indicated that the light microscope appearance of tumor T47 did not meet all three criteria of anaplasia (see Introduction), but some tumor cells were present that met one or two of those criteria. This might suggest a mis-sampling in histological examination of this case. While the disease progression of these three patients was concordant with the concept that anaplastic tumors progresses from FH tumors, the 97 clones we identified were capable of capturing the molecular differences between these two subtypes of Wilms tumors. Anaplastic nuclear changes are associated with increased resistance to adjuvant therapy (Beckwith and Palmer, 1978; Bonadio et al., 1985) . As expected, we recognized several genes among the 97 clones (76 genes) that may contribute either to nuclear morphology or therapeutic resistance (Table 2 ). These include Huntingtin, hRAD54, CENPA, CENPF, NuSAP1, hMPS1/ TTK, MCAK/KIF2C, BRRN1/hCAP-H, importin alpha 1/KPNA2 (all expressed higher in anaplastic tumors than in FH tumors) and IFI16, caspase-10, TACC1 (all expressed lower in anaplastic tumors than in FH tumors) (see Discussion). Some genes that we found to be differentially expressed between anaplastic and FH Wilms tumors likely reflect a higher proliferative rate in anaplastic tumors. These include cell division control protein CDC2, cell division cycle-associated 3/TOME1, antigen Ki-67 and cyclin A1 (all expressed higher in anaplastic tumors than in FH tumors) and cyclindependent kinase inhibitor p21 and Rb binding protein 6 (all expressed lower in anaplastic tumors than in FH tumors). In addition, it is noted that WHSC1, the WolfHirschhorn syndrome candidate gene 1, is expressed at a higher level in anaplastic tumors than in FH tumors.
Confirmation of array results by real-time PCR
Four genes were arbitrarily chosen to validate their expression patterns in FH and anaplastic tumors by real-time PCR. As measured by real-time PCR, the expression of Huntingtin and WHSC1 in anaplastic tumors was 3.18-fold (two-tailed t-test P-value ¼ 0.0053) and 2.70-fold (two-tailed t-test P-value ¼ 0.0087) of that in FH tumors, respectively. Conversely, expression of p21 and TACC1 in FH tumors was 2.59-fold (two-tailed t-test P-value ¼ 0.01) and 1.50 fold (two-tailed t-test Pvalue ¼ 0.09) of that in anaplastic tumors ( Figure 5 ). These real-time PCR results were consistent with the cDNA array data. It should be pointed out that expression of any one of these four genes on its own is not sufficient to distinguish anaplastic tumors from FH tumors; rather, a set of multiple genes (for example, the 97 clones identified by PAM) provides maximal discriminating power.
Discussion
Wilms tumor and kidney morphogenesis
Here, we demonstrate that the gene expression patterns of Wilms tumors parallel the MET that occurs during the early stage of kidney development. Our analysis provides the first large-scale gene expression connection between Wilms tumors and kidney morphogenesis. To our knowledge, it is also the first time for many of these genes to be linked between development (nephrogenesis) and cancer (Wilms tumor).
Some genes in Category 1 have been directly implicated in the MET, including neural cell adhesion molecule (NCAM), transforming growth factor beta receptor II/TGFBR2, oncogene N-myc, syndecan 1/ SDC1, bone morphogenetic protein (BMP)7 and homeobox protein Lim-1. NCAM has been showed to be expressed in embryonic kidney and Wilms tumor, but is undetectable in normal adult kidney (Roth et al., 1988) . It is expressed in the condensing mesenchyme of the metanephros, and downregulated as epithelial conversion occurs (Roth et al., 1989) , similar to TGFBR2 (Wang et al., 1995) and N-myc (Mugrauer et al., 1988; Bates et al., 2000) . It has also been shown that when N-myc expression is downregulated, cells progress through differentiation and acquire their terminal phenotype (Stanton and Parada, 1992) . In mice, complete disruption of the N-myc gene results in fetal death on the first day of renal organogenesis (Sawai et al., 1991; Charron et al., 1992) . Interestingly, the Wilms tumor suppressor gene WT1 is upregulated in MM soon after the beginning of differentiation (Pritchard-Jones et al., 1990; Pelletier et al., 1991; Armstrong et al., 1993) , the same time when N-myc expression decreases. Since WT1 has been revealed as a repressor of the N-myc promoter (Zhang et al., 1999) , overexpression of N-myc may be one of the consequences of WT1 mutations/dysfunction in Wilms tumorigenesis. Syndecan 1 is a cell surface proteoglycan whose induction is coincident with epithelial differentiation during kidney development and whose loss of expression is correlated with the loss of the epithelial phenotype and malignant transformation (Cook et al., 1996) . Unlike N-myc, syndecan 1 promoter is activated by WT1 (Cook et al., 1996) , suggesting that its downregulation may also mediate WT1 mutations/dysfunction in Wilms tumor development.
BMP7 plays important roles in normal kidney development. Purified BMP7 induces differentiation of MM in vitro and inhibition of BMP7 activity through neutralizing antibodies or antisense oligonucleotides blocks kidney development (Vukicevic et al., 1996) . In BMP7-deficient mice, kidney development initiates but fewer or even no nephrons are formed (Luo et al., 1995) . Abnormal attenuation of BMP7 expression during nephrogenesis could lead to the accumulation of cycling stem cells as in Wilms tumors. Consistent with this, striking reduction of BMP7 expression has been found in the blastemal and epithelial cells of a rat model of nephroblatsoma (Higinbotham et al., 1998) . Wnt-4, together with BMP7 as regulators for nephron maturation, is also required for the epithelium formation in the induced metanephros (Stark et al., 1994) . Although no differential expression for Wnt4 between Wilms tumors and fetal kidney was detected in our study, its receptor FZD1 and frizzled-related protein were shown to be downregulated in Wilms tumors (Table 1) .
Lim-1, also termed LHX1, is expressed in the UB, in induced mesenchymal aggregates, in comma-and Sshaped bodies and in developing tubules (Barnes et al., 1994; Fujii et al., 1994; Karavanov et al., 1998) . Results from Lim-1 null mice suggest that Lim-1 is essential at least for early kidney morphogenesis (Shawlot and Behringer, 1995) . The molecular mechanisms by which Lim-1 contributes to kidney development and potentially Wilms tumor etiology are not known, but it is frequently methylated and downregulated in pancreatic cancers (Sato et al., 2003) . In future, it will be interesting to examine whether Lim-1 is also methylated in Wilms tumors and whether this contributes to Wilms tumorigenesis.
Genes in Categories 2 and 3 have been implicated in Wilms tumors. Notably, some genes in Category 2 (such as APOE and TIEG) and all genes in Category 3 have been classified as early or late nephrogenic genes by expression profiling (Stuart et al., 2001) . Owing to the putative linkage of Wilms tumor to nephrogenesis, potential roles in normal kidney development for genes in these categories could be explored further. Stathmin 1 gene, one of these genes, encodes a cytosolic phosphoprotein that regulates the microtubule filament system by destabilizing the microtubules and is proposed to act as an intracellular relay integrating regulatory signals of the cellular environment (Sobel, 1991; Wittmann et al., 2004) . The expression pattern of stathmin 1 protein in human fetal kidney (Figure 3b ) suggests that it may be involved in proliferation and differentiating processes during normal kidney development. Its significance to nephrogenesis remains to be determined. In addition, our observation that stathmin 1 protein is overexpressed in Wilms tumors is consistent with the transcript profiling and its elevated expression in other human cancers, including leukemia, osteosarcoma and breast cancer (Belmont and Mitchison, 1996; Alli et al., 2002; Zhang et al., 2004) .
It is noted that WHSC1was found to be overexpressed in Wilms tumors compared to fetal kidney, especially in anaplastic tumors (Tables 1 and 2 ). Wolf-Hirschhorn syndrome is caused by deletion of the WHSC1 gene locus in 4p16.3 and characterized by severe pre-and postnatal growth retardation, including malformations of the urogenital system (Grisaru et al., 2000) . The WHSC1 gene is expressed in early development and preferentially in rapidly growing embryonic tissues (Stec et al., 1998) . Interestingly, the WHSC1 gene is fused to IgH and overexpressed in t(4;14) multiple myeloma (Stec et al., 1998; Malgeri et al., 2000) . These observations suggest that WHSC1 may promote proliferation and thus function as oncogene in some circumstances including Wilms tumor, and may also play a role in kidney development.
An expression signature for anaplastic Wilms tumor
Three methods were used to identify genes distinguishing anaplastic tumors from FH tumors, including Welch's t-test with multiple testing correction, SAM and PAM. The latter was the most satisfactory in terms of the performance in hierarchically clustering and crossvalidation, which demonstrated the value of applying more than one method in data analysis.
It has been clearly shown that p53 mutations are associated with anaplasia of Wilms tumors (Bardeesy et al., 1994 (Bardeesy et al., , 1995 Malkin et al., 1994; Lahoti et al., 1996) . It is likely that they also occur in the anaplastic Wilms tumors we have analysed. In fact, a p53 mutation has been characterized for one of the anaplastic tumors in our study (T53 in this study ¼ WiT34 metastasis in Lahoti et al., 1996) . The classic p53 target gene p21 was downregulated in the anaplastic Wilms tumors, indicating a deficiency in p53 activity in these tumors. Additional evidence comes from our recent work where we have demonstrated that Podocalyxin, a gene upregulated in anaplastic Wilms tumors, was transcriptionally repressed by p53 in a Wilms tumor cell line (Stanhope-Baker et al., 2004) .
The molecular bases underlying the anaplastic nuclear morphology remain unknown. It is intriguing to note that several genes known to control spindle organization, chromosome condensation and nuclei separation during mitosis are dysregulated in anaplastic tumors, such as centromeric protein genes CENPA and CENPF, nucleolar spindle-associated protein gene NuSAP1, spindle checkpoint gene hMPS1/TTK, mitotic centromere-associated kinesis gene MCAK/KIF2C, chromosome condensation factor gene BRRN1/hCAP-H, importin alpha 1/KPNA2 (expressed higher in anaplastic tumors) and transforming acidic coiled-coil containing protein TACC1 (expressed lower in anaplastic tumors).
NuSAP1 has been suggested to play a crucial role in spindle microtubule organization (Raemaekers et al., 2003) . TTK localizes to kinetochores and is required for spindle assembly checkpoint (Stucke et al., 2002) . MCAK also localizes to inner kinetochores but is predominantly centromeric in metaphase. Depletion of centromeric MCAK leads to chromosome congression and segregation defect due to improper kinetochore attachments (Kim et al., 1997; Sugata et al., 2000; KlineSmith et al., 2004) . hCAP-H plays a central role in mitotic chromosome condensation (Cabello et al., 2001; Kimura et al., 2001) . SRP1, the yeast homologous of KPNA2, has been shown to be critical for normal migration, division and integrity of nuclei during mitosis (Kussel and Frasch, 1995) . On the other hand, the transforming acidic coiled-coil containing protein family is known to interact with centrosomes and microtubules (Raff, 2002) . Depletion of human TACC1 perturbs normal cell division and it has been shown to be downregulated in various types of human cancers (Conte et al., 2002) . Dysregulation of these genes that appear to be critical for normal mitosis and integrity of nuclei could be responsible for the nuclear changes in anaplastic Wilms tumors. Disruption of normal mitotic spindle assembly typically leads to cell apoptosis via the p53 pathway (Amundson et al., 1998; Schwartz and Rotter, 1998) . However, since p53 functions may have been defective in anaplastic tumors (Bardeesy et al., 1994 (Bardeesy et al., , 1995 , the tumor cells in which mitosis had occurred abnormally would not be eliminated and could re-enter the cell cycle, eventually becoming anaplastic cells. These resultant nuclear changes may generate T17  T18  T38  T53  T46  T49  T50  T52  T11  T12  T1  T2  T3  T14  T8  T9   WHSC1  17   0   1   2   3   4   5   6   7   T17  T18  T38  T53  T46  T49  T50  T52  T11  T12  T1  T2  T3  T14  T8  T9   T17  T18  T38  T53  T46  T49  T50  T52  T11  T12  T1  T2  T3  T14  T8  T9  T17  T18  T38  T53  T46  T49  T50  T52  T11  T12  T1  T2  T3  T14  T8  T9   TACC1 genetic instability that could contribute to development of this adverse subtype of Wilms tumor. Observations in line with this include the finding that anaplastic Wilms tumors display more chromosomal abnormalities than FH Wilms tumors (Gow and Murphy, 2002) . Attenuated apoptosis has been seen in anaplastic tumors, which may explain, at least partially, its poor responsiveness to adjuvant therapy (Bardeesy et al., 1995; Tanaka et al., 1999) . We also identified several genes implicated in apoptosis, such as the Huntington disease gene Huntingtin, the double-strand DNA break repair gene hRAD54 (expressed higher in anaplastic tumors than in FH tumors), gamma-interferon-inducible gene IFI16 and caspase-10 (expressed lower in anaplastic tumors than in FH tumors). Wild-type Huntingtin has been shown to be antiapoptotic by inhibiting the conversion of procaspase-9 into active caspase-9 (Rigamonti et al., 2000) . Huntingtin also regulates the transcription of BDNF (Zuccato et al., 2001) . Notably, BDNF and its receptor TrkB contribute to the chemotherapy resistance of neuroblastoma (Ho et al., 2002; Jaboin et al., 2002) and high expression level of functional TrkB is associated with unfavorable outcome of Wilms tumor (Eggert et al., 2001) . Increased expression of Huntingtin in anaplastic tumors might have led to inhibition of apoptosis and induction of BDNF and/or TrkB in the tumors. Reduced homologous recombination and ionizing radiation or X-ray resistance have been observed in RAD54 deficiency yeast, Drosophila, chick cells and mice (Bezzubova et al., 1997; Clever et al., 1997; Essers et al., 1997; Kooistra et al., 1997 Kooistra et al., , 1999 . Elevation of hRAD54 expression in anaplastic tumors may also contribute to their therapy resistant phenotype. On the other hand, IFI16 is shown to interact with BRCA1 and has proapoptotic activities under conditions of DNA damage and the apoptotic pathways involved IFI16 is known be mediated by p53 (Aglipay et al., 2003) .
The expression patterns and implications in apoptosis render Huntingtin (and its downstream genes BDNF or TrkB) and hRAD54 potential targets for gene ablation therapy to treat anaplastic Wilms tumors. A truncated polyQ-expanded Huntingtin containing 63 N-terminal amino acids and 99 consecutive glutamine residues has been shown to form aggregates and induce toxicity in mouse HT22 hippocampal neuronal cells (Jiang et al., 2003) . Expression of similar mutant proteins in Wilms tumors may induce apoptosis or increase their drug sensitivity. Reduced resistance to ionizing radiation or X-ray has been seen in several model systems where RAD54 gene is deficient. Similar effects may take place in Wilms tumors when the hRAD54 gene is ablated.
In conclusion, this study has revealed a number of intriguing connections between kidney morphogenesis and Wilms tumor, and identified genes potentially contributing to the nuclear morphology and therapy resistance phenotype of anaplastic tumors. Our findings highlight pathways that might be important in the etiology of Wilms tumors in general or anaplasia specifically. These might be exploited to improve treatment of Wilms tumors.
Materials and methods
Cancer cDNA array construction
The cancer cDNA array used in this study contained probes for 9240 cDNA clones corresponding to 4900 Unigenes or unclustered ESTs relevant to cancer or kidney development. These include: (1) 1800 genes implicated in metastasis or cancer development in general from the literature (Scholl et al., 2000; Hippo et al., 2001) and from the Affymetrix cancer G110 array (www.affymetrix.com/analysis/index.affx); (2) 1809 genes involved in kidney development (golgi.ana.ed.ac.uk/ kidhome.html) or showing more than threefold variation of expression among four primary Wilms tumors and fetal kidney in our Affymetrix GeneChip experiments (unpublished data); (3) 1400 potential downstream genes of p53; (4) 950 genes with AU-rich elements in their 3 0 -and/or 5 0 -untranslated region (UTR) (Frevel et al., 2003) ; and (5) 1245 cytokine responsive genes, genes for zinc-finger proteins or genes implicated in apoptosis. Construction of the array was similar to that described previously (Frevel et al., 2003) .
Sample collection, array experiment and data processing
In all, 54 Wilms tumor samples, five normal kidney tissue samples and two Wilms tumor cell lines were obtained from the Cleveland Clinic Foundation (Cleveland, OH, USA), the Hospital for Sick Children (Toronto, Canada) and the National Wilms Tumor Study Group (NWTS) under IRB approval (Supplementary Table 1 for clinical information). Pooled RNA from 13-to 24-week-old human fetal kidneys (Stratagene) was used as a universal control for the array experiments. Duplicate experiments were performed for two of the 54 Wilms tumors. Altogether, there were 63 data files.
GeneSpring software (Silicongenetics) was used for data analyses. Intensities below 100 were raised to 100 and nonlinear normalization (LOWESS) was performed for each array to yield the abundance of each transcript in a tumor sample as an intensity ratio with respect to its abundance in human fetal kidney.
Hierarchical clustering analyses
The 2000 features with the greatest variation in expression across the 63 data files as measured by the coefficient of variation (CV ¼ standard deviation of expression of a feature in all samples/mean of expression of that feature in all samples) were selected and used for agglomerative hierarchical clustering analysis. Clustering was based on average linkage and Pearson's correlation similarity measurements.
cDNA microarray comparisons between Wilms tumors and fetal kidney
In total, 31 stage I or II Wilms tumors were compared to the same pooled human fetal kidney sample. A cDNA clone was considered upregulated (or downregulated) in Wilms tumors if its expression fulfilled the following two criteria: (a) intensities in the tumors (or in fetal kidney) above 300, called present and expressed at >1.5-fold higher (or lower), in at least 16 of the 31 tumor/fetal kidney comparisons; (b) one sample t-test two-sided P-value o0.01. Data for temporal gene expression patterns during rat kidney development were downloaded from http://organogenesis.ucsd.edu/data.html (Stuart et al., 2001) . Current gene information and human homologs for the rat genes in the temporal expression patterns (Stuart et al., 2001) were obtained from recently updated Affymetrix databases (www.affymetrix.com/analysis/ index.affx). In this way, genes that showed altered expression in Wilms tumors were annotated as early or late nephrogenic genes. The kidney development (http://golgi. ana.ed.ac.uk/kidhome.html) and PubMed databases were explored to establish connections for genes differentially expressed in Wilms tumors vs fetal kidney and in those important specific morphogenic structures during kidney development.
IHC staining
A Wilms tumor tissue microarray consisting 15 pairs of Wilms tumor and normal adjacent kidney tissues and two unpaired Wilms tumor tissues was constructed following procedure similar to that described previously (Skacel et al., 2002) . Paraffin-embedded tissue sections representing fetal kidney (Abcam Ltd, UK) or the Wilms Tumor Tissue Array were processed for immunohistochemistry using stathmin 1 antibody (Cell Signaling #3352, 1:50) following the manufacturer's procedure. Slides were then examined with a Leica DMR microscope.
Identification of gene expression patterns associated with anaplastic Wilms tumor
Three methods were used to search for genes differentially expressed between FH tumors and anaplastic tumors. In the Welch t-test, the false discovery rate controlled by Benjamini and Hochberg procedure was used to adjust P-values to test genes for differential expression between FH tumors and anaplastic tumors. SAM was also used to identify significantly differentiated genes (Tusher et al., 2001; Higgins et al., 2003; Sperger et al., 2003) . False discovery rate is used to threshold the t-statistics to produce a 'significant' gene list. PAM was used to search for the smallest set of genes that could differentiate FH tumors and anaplastic tumors (Tibshirani et al., 2002; Korkola et al., 2003; Korshunov et al., 2003) . Gene sets identified by the three methods were each evaluated with regard to their performance in distinguishing anaplastic tumors from FH tumors by agglomerative hierarchical clustering and leave-one-off crossvalidation using the knearest-neighbor algorithm.
Real-time PCR
cDNA was reverse-transcribed from 1.5 mg of total RNA using random primering. Expression levels of Huntingtin, WHSC1, TACC1 and p21 were determined using the following primers with SYBR Green Master Mix on an ABI 7700 system. Huntingtin forward primer: 5 0 -GCTTCCTCAGCCCTA-GAGGC-3 0 ; reverse primer: 5 0 -GCATGACCAAACCAAGC CA-3 0 ; WHSC1 forward primer: 5 0 -CCAACGGGAAGACT CCGAG-3 0 ; reverse primer: 5 0 -TGGGCTTTGCTGAGGAA CA-3 0 ; TACC1 forward primer: 5 0 -ACAGGGCAGCGTG TAGGTG-3 0 ; reverse primer: 5 0 -ATCCTATCCCGACGGCT GA-3 0 ; p21 forward primer: 5 0 -TGGAGACTCTCAGGGTC GAAA-3 0 ; reverse primer: 5 0 -CGGCGTTTGGAGTGGTA GAA-3 0 . Each PCR primer pair was tested to ensure that a single PCR product of expected size was produced before being used in SYBR Green real-time PCR assays. The quality and amount of input cDNA was assessed by amplification of 18s rRNA sequences using a commercially available primer/ probe set with TaqMan Master Mix (both from Perkin-Elmer). A DCT value ( ¼ CT gene ÀCT 18s rRNA ) was calculated for each gene in each sample. The Welch t-test was used to assess the significance level of DCT difference between FH tumors and anaplastic tumors.
Abbreviations FH, favorable histology; UTR, untranslated region; CT, cycle of threshold.
